

**Interim Financial Statements (Un-audited)
January - September, 2014**



Beximco Pharmaceuticals Limited

Beximco Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at September 30, 2014

		As at September 30, 2014	Taka '000 As at December 31, 2013
ASSETS			
Non-Current Assets		19,627,052	18,567,329
Property, Plant and Equipment- Carrying Value	3	19,353,803	18,364,313
Intangible Assets		266,511	198,223
Investment in Shares		6,738	4,793
Current Assets		8,930,848	8,903,422
Inventories	4	2,522,773	2,411,882
Spares & Supplies		462,480	433,352
Accounts Receivable		1,408,573	1,249,435
Loans, Advances and Deposits	5	1,246,892	1,186,637
Short Term Investment		3,184,373	3,026,383
Cash and Cash Equivalents	6	105,757	595,733
TOTAL ASSETS		28,557,900	27,470,751
EQUITY AND LIABILITIES			
Shareholders' Equity		20,545,796	19,775,552
Issued Share Capital		3,678,516	3,503,349
Share Premium		5,269,475	5,269,475
Excess of Issue Price over Face Value of GDRs		1,689,637	1,689,637
Capital Reserve on Merger		294,951	294,951
Revaluation Surplus		1,302,132	1,349,579
Fair Value Gain on Investment		3,287	1,341
Retained Earnings		8,307,798	7,667,220
Non-Current Liabilities		3,352,098	3,312,618
Long Term Borrowings-Net off Current Maturity (Secured) 7 A		915,208	1,151,401
Liability for Gratuity and WPPF & Welfare Funds		726,311	610,628
Deferred Tax Liability		1,710,579	1,550,589
Current Liabilities and Provisions		4,660,006	4,382,581
Short Term Borrowings (Secured)		3,114,942	2,776,266
Long Term Borrowings-Current Maturity (Secured) 7 B	7 B	802,442	754,904
Creditors and Other Payables		261,405	383,171
Accrued Expenses		107,661	141,582
Dividend Payable		455	973
Income Tax Payable		373,101	325,685
TOTAL EQUITY AND LIABILITIES		28,557,900	27,470,751

Nazmul Hassan

Nazmul Hassan
 Managing Director

Ali Nawaz

Ali Nawaz
 Chief Financial Officer

Beximco Pharmaceuticals Limited
Statement of Comprehensive Income (Un-audited)
For the Period January - September, 2014

	Notes	January - September 2014	January - September 2013	July - September 2014	July - September 2013
					Taka '000
Net Sales Revenue		8,268,693	7,620,072	2,946,421	2,653,714
Cost of Goods Sold	8	(4,505,873)	(4,157,452)	(1,600,605)	(1,428,686)
Gross Profit		<u>3,762,820</u>	<u>3,462,620</u>	<u>1,345,816</u>	<u>1,225,028</u>
Operating Expenses		<u>(1,988,341)</u>	<u>(1,802,046)</u>	<u>(704,085)</u>	<u>(612,551)</u>
Administrative Expenses	9	(331,508)	(286,165)	(117,030)	(90,001)
Selling, Marketing and Distribution Expenses	10	(1,656,833)	(1,515,881)	(587,055)	(522,550)
Profit from Operations		<u>1,774,479</u>	<u>1,660,574</u>	<u>641,731</u>	<u>612,477</u>
Other Income		416,111	378,530	156,248	131,012
Finance Cost		(504,794)	(434,320)	(181,624)	(142,102)
Profit Before Contribution to WPPF & Welfare Funds		<u>1,685,796</u>	<u>1,604,784</u>	<u>616,355</u>	<u>601,387</u>
Contribution to WPPF & Welfare Funds		(80,276)	(76,418)	(29,350)	(28,637)
Profit Before Tax		<u>1,605,520</u>	<u>1,528,366</u>	<u>587,005</u>	<u>572,750</u>
Income Tax Expenses		<u>(451,487)</u>	<u>(445,186)</u>	<u>(157,245)</u>	<u>(148,074)</u>
Current Tax		(326,898)	(325,565)	(119,783)	(122,049)
Deferred Tax		(124,589)	(119,621)	(37,462)	(26,025)
Profit After Tax		<u>1,154,033</u>	<u>1,083,180</u>	<u>429,760</u>	<u>424,676</u>
Other Comprehensive Income - Fair Value Gain on Investment in Listed Shares		1,946	1,092	1,451	1,092
Total Comprehensive Income		<u>1,155,979</u>	<u>1,084,272</u>	<u>431,211</u>	<u>425,768</u>

Earnings Per Share (EPS) / Adjusted EPS (2013) Tk.	3.14	2.94	1.17	1.15
Number of Shares used to compute EPS	367,851,652	367,851,652	367,851,652	367,851,652

Nazmul Hassan

Nazmul Hassan
Managing Director

Ali Nawaz

Ali Nawaz
Chief Financial Officer

Beximco Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the Period January - September, 2014

Taka '000

As at September 30, 2014								
	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Fair Value Gain on Investment	Retained Earnings	Total
Balance as at January 01, 2014	3,503,349	5,269,475	1,689,637	294,951	1,349,579	1,341	7,667,220	19,775,552
Total Comprehensive Income for the Period :								
Profit for the Period	—	—	—	—	—	—	1,154,033	1,154,033
Other Comprehensive Income	—	—	—	—	—	1,946	—	1,946
Cash Dividend for 2013	—	—	—	—	—	—	(350,334)	(350,334)
Stock Dividend for 2013	175,167	—	—	—	—	—	(175,167)	—
Adjustment for Depreciation on Revalued Assets	—	—	—	—	(12,046)	—	12,046	—
Adjustment for Deferred Tax on Revalued Assets	—	—	—	—	(35,401)	—	—	(35,401)
Balance as at September 30, 2014	3,678,516	5,269,475	1,689,637	294,951	1,302,132	3,287	8,307,798	20,545,796

Number of Shares on September 30, 2014

367,851,652

Net Asset Value (NAV) Per Share

Tk. 55.85

As at September 30, 2013								
	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Fair Value Gain on Investment	Retained Earnings	Total
Balance as at January 01, 2013	3,046,390	5,269,475	1,689,637	294,951	1,406,528	—	6,701,181	18,408,162
Total Comprehensive Income for the Period :								
Profit for the Period	—	—	—	—	—	—	1,083,180	1,083,180
Other Comprehensive Income	—	—	—	—	—	1,092	—	1,092
Stock Dividend for 2012	456,959	—	—	—	—	—	(456,959)	—
Adjustment for Depreciation on Revalued Assets	—	—	—	—	(13,676)	—	13,676	—
Adjustment for Deferred Tax on Revalued Assets	—	—	—	—	(39,967)	—	—	(39,967)
Balance as at September 30, 2013	3,503,349	5,269,475	1,689,637	294,951	1,352,885	1,092	7,341,078	19,452,467

Number of Shares on September 30, 2013

350,334,907

Net Asset Value (NAV) Per Share

Tk. 55.53

Nazmul Hassan

Nazmul Hassan
Managing Director

Ali Nawaz

Ali Nawaz
Chief Financial Officer

Beximco Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the Period January – September, 2014

	January- September 2014	Taka '000 January- September 2013						
Cash Flows from Operating Activities :								
Receipts from Customers and Others	8,124,320	7,471,783						
Payments to Suppliers and Employees	(6,243,342)	(6,053,606)						
Cash Generated from Operations	1,880,978	1,418,177						
Interest Paid	(504,794)	(434,320)						
Interest Received	399,822	380,041						
Income Tax Paid	(279,482)	(195,807)						
Net Cash Generated from Operating Activities	1,496,524	1,168,091						
Cash Flows from Investing Activities :								
Acquisition of Property, Plant and Equipment	(1,552,551)	(509,566)						
Intangible Assets	(80,498)	(36,593)						
Disposal of Property, Plant and Equipment	5,370	60						
Short Term Investment	(157,990)	(238,691)						
Net Cash Used in Investing Activities	(1,785,669)	(784,790)						
Cash Flows from Financing Activities :								
Net Increase / (Decrease) in Long Term Borrowings	(188,655)	(105,269)						
Net Increase / (Decrease) in Short Term Borrowings	338,676	(252,608)						
Dividend Paid	(350,852)	(22)						
Net Cash Generated from Financing Activities	(200,831)	(357,899)						
Increase / (Decrease) in Cash and Cash Equivalents	(489,976)	25,402						
Cash and Cash Equivalents at Beginning of Period	595,733	552,979						
Cash and Cash Equivalents at End of Period	105,757	578,381						
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Net Operating Cash Flow Per Share</td> <td style="width: 20%; text-align: center;">Tk. 4.07</td> <td style="width: 20%; text-align: center;">3.33</td> </tr> <tr> <td>Number of Shares used to compute Net Operating Cash Flow Per Share</td> <td style="text-align: center;">367,851,652</td> <td style="text-align: center;">350,334,907</td> </tr> </table>			Net Operating Cash Flow Per Share	Tk. 4.07	3.33	Number of Shares used to compute Net Operating Cash Flow Per Share	367,851,652	350,334,907
Net Operating Cash Flow Per Share	Tk. 4.07	3.33						
Number of Shares used to compute Net Operating Cash Flow Per Share	367,851,652	350,334,907						

Nazmul Hassan

Nazmul Hassan
Managing Director

Ali Nawaz

Ali Nawaz
Chief Financial Officer

Beximco Pharmaceuticals Limited
Selected Notes to the Financial Statements (Un-audited)
For the Period January – September, 2014

1. Reporting Entity

Beximco Pharmaceuticals Limited (BPL/the Company) is a public company incorporated in Bangladesh in 1976. It commenced its manufacturing operation in 1980. The company is listed on Dhaka and Chittagong Stock Exchanges of Bangladesh and AIM of London Stock Exchange. The company is engaged in manufacturing and marketing of Pharmaceuticals Finished Formulation Products, Active Pharmaceutical Ingredients (APIs) and life saving Intravenous Fluids which it sells in the local as well as international markets. The registered office of the company is located at House no. 17, Road No. 2, Dhanmondi R/A, Dhaka. The Industrial units are located at Tongi and Kaliakoir of Gazipur District - vicinities close to the capital city Dhaka.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the year ended December 31, 2013 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

Taka '000

	As at September 30, 2014	As at December 31, 2013
3. Property, Plant & Equipment		
Cost / Revaluation		
Land	3,343,741	3,302,883
Building and Other Constructions	6,378,690	6,370,759
Plant & Machinery	10,529,326	10,034,644
Furniture & Fixture	186,073	173,334
Transport & Vehicle	578,818	548,077
Office Equipment	385,235	358,363
	21,401,883	20,788,060
Less : Accumulated Depreciation	(5,241,638)	(4,686,815)
Net Book Value	16,160,245	16,101,245
Capital Work in Progress	3,193,558	2,263,068
Carrying Value	<u>19,353,803</u>	<u>18,364,313</u>

Taka '000

	As at September 30, 2014	As at December 31, 2013
4. Inventories		
Finished Goods	602,407	644,006
Raw and Packing Material (Including Work in Process and Transit)	1,819,561	1,675,642
Physician Sample	100,805	92,234
	<u>2,522,773</u>	<u>2,411,882</u>
5. Loans, Advances and Deposits		
Clearing & Forwarding	56,591	43,789
VAT	223,805	224,272
Security Deposit and Earnest Money	25,472	21,814
Capital Expenditure / Project	41,259	39,234
Advance against Salary	49,872	51,306
Motor Cycle	131,436	156,329
Raw & Packing Material	471,973	409,578
Overseas Liaison Office	10,109	9,969
Expenses	131,486	85,456
Bank Guarantee Margin	1,257	39,940
Others	103,632	104,950
	<u>1,246,892</u>	<u>1,186,637</u>
6. Cash and Cash Equivalents		
(a) Cash In Hand (Including Imprest Cash)	1,805	3,475
(b) Cash at Bank:		
i) Current & FC Account	76,059	85,680
ii) FDR Account	27,893	506,578
	<u>105,757</u>	<u>595,733</u>
7A. Long Term Borrowings - Net off Current Maturity (Secured)		
Project Loan	606,044	1,001,325
Obligation Under Finance Leases	309,164	150,076
	<u>915,208</u>	<u>1,151,401</u>
7B. Long Term Borrowings - Current Maturity (Secured)		
Project Loan	674,677	652,690
Obligation Under Finance Leases	127,765	102,214
	<u>802,442</u>	<u>754,904</u>

Taka '000

January-
September 2014

January-
September 2013

8. Cost of Goods Sold

Materials	3,202,590	3,052,356
Factory Overhead	797,195	714,270
Depreciation	506,088	390,826
	<u>4,505,873</u>	<u>4,157,452</u>

9. Administrative Expenses

Salary & Allowances	148,217	131,300
Repairs & Maintenance	26,599	23,016
Travelling & Conveyance	16,895	15,224
AGM, Company Secretarial and Regulatory Expenses	38,008	44,908
Depreciation	19,572	15,115
Other Expenses	82,217	56,602
	<u>331,508</u>	<u>286,165</u>

10. Selling, Marketing and Distribution Expenses

Salary & Allowances	532,276	476,427
Travelling & Conveyance	220,987	201,626
Market Research & New Products	29,759	26,966
Sample, Literature & Promotional Expenses	483,230	444,325
Delivery Expense	245,635	228,584
Depreciation and Amortization	45,764	36,506
Other Expenses	99,182	101,447
	<u>1,656,833</u>	<u>1,515,881</u>

Nazmul Hassan

Nazmul Hassan
Managing Director

Ali Nawaz

Ali Nawaz
Chief Financial Officer